Staff reviewers at the U.S. Food and Drug Administration identified several uncertainties with Veru Inc's data for oral COVID-19 pill for treating moderate-to-severe hospitalized patients at high risk of developing an acute respiratory distress syndrome, according to briefing documents published on Monday.
https://finance.yahoo.com/news/fda-staff-flags-several-uncertainties-142701019.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.